Companies to collaborate on facilitating clinical trials in historically underserved regions.
Guardian Research Network (GRN) announced in a company press release that it has been joined by Clemson Rural Health to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN’s healthcare database is expected to help Clemson Rural Health bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.
"Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman, CEO, GRN. "Bringing this innovative team into our consortium demonstrates our unwavering commitment to improving access to cutting-edge studies in underserved communities. I look forward to the work we will accomplish together in our shared mission of driving community health advancements."
Reference: Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health. PR Newswire. October 3, 2023. Accessed October 10, 2023. https://www.prnewswire.com/news-releases/clemson-rural-health-joins-forces-with-guardian-research-network-to-improve-community-health-301945161.html
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.